Recombinant Human CDK8, GST-tagged

• Cat.No.: CDK8-11H
• Product Overview: Recombinant Human CDK8(1 a.a. - 464 a.a.), fused with GST-tag at N-terminal, was expressed in wheat germ.

Specification

• Description: The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This kinase and its regulatory subunit cyclin C are components of the RNA polymerase II holoenzyme complex, which phosphorylates the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II. This kinase has also been shown to regulate transcription by targeting the CDK7/cyclin H subunits of the general transcription initiation factor IIH (TFIIH), thus providing a link between the 'Mediator-like' protein complexes and the basal transcription machinery.
• Source: Wheat germ
• Species: Human
• Tag: GST
• Molecular Mass: 79.7 kDa
• AA Sequence: MDYDFKVKLSSERERVEDLFEYEGC KVGRGTYGHVYKAKRKDGKDDKDYA LKQIEGTGISMSACREIALLRELKH PNVISLQKVFLSHADRKVWLLFDYA EHDLWHIIKFHRASKANKKPVQLPR GMVKSLLYQILDGIHYLHANWVLHR DLKPANILVMGEGPERGRVKIADMG FARLFNSPLKPLADLDPVVVTFWYR APELLLGARHYTKAIDIWAIGCIFA ELLTSEPIFHCRQEDIKTSNPYHHD QLDRIFNVMGFPADKDWEDIKKMPE HSTLMKDFRRNTYTNCSLIKYMEKH KVKPDSKAFHLLQKLLTMDPIKRIT SEQAMQDPYFLEDPLPTSDVFAGCQ IPYPKREFLTEEEPDDKGDKKNQQQ QQGNNHTNGTGHPGNQDSSHTQGPP LKKVRVVPPTTTSGGLIMTSDYQRS NPHAAYPNPGPSTSQPQSSMGYSAT SQQPPQYSHQTHRY
• Applications: ELISA; WB-Re; AP; Array
• Notes: Best use within three months from the date of receipt of this protein.
• Storage: Store at -80ºC. Aliquot to avoid repeated freezing and thawing.
• Storage Buffer: 50 mM Tris-HCI, 10 mM reduced Glutathione, pH=8.0 in the elution buffer.

Gene Information

• Gene Name: CDK8 cyclin-dependent kinase 8 [ Homo sapiens (human) ]
• Official Symbol: CDK8
• Synonyms: cyclin-dependent kinase 8; K35; MGC126074; MGC126075; protein kinase K35; CDK8 protein kinase; cell division protein kinase 8; EC 2.7.11.22,EC 2.7.11.23; Protein kinase K35; CDK8; OTTHUMP00000018158; Mediator complex subunit CDK8; Mediator of RNA polymerase II transcription subunit CDK8
• Gene ID: 1024
• mRNA Refseq: NM_001260
• Protein Refseq: NP_001251
• MIM: 603184
• UniProt ID: P49336
• Chromosome Location: 13q12
• Pathway: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants; Developmental Biology; Fatty acid, triacylglycerol, and ketone body metabolism
• Function: ATP binding; RNA polymerase II carboxy-terminal domain kinase activity; cyclin-dependent protein serine/threonine kinase activity; protein binding

Reviews

03/05/2020

The CDK8 protein stands as a remarkable solution that exemplifies exceptional quality and meets all my experimental requirements.

08/03/2019

I am confident that the CDK8 protein will unlock vital insights into cellular processes, propelling my scientific investigations to new heights.

10/01/2017

Its impressive purity and functional characteristics make it an ideal choice for my research endeavors, ensuring reliable and impactful results.

Q&As

Is CDK8 exclusively associated with cancer, or does it have physiological roles in normal cellular functions?

CDK8 plays essential roles in normal cellular functions, including development and tissue homeostasis. Its dysregulation, however, is implicated in cancer.

Can CDK8 inhibitors be used in combination with other cancer treatments, and if so, what are the potential benefits?

Combination therapies involving CDK8 inhibitors are being explored to enhance treatment outcomes and reduce the likelihood of resistance, providing a more comprehensive approach to cancer management.

How does CDK8 inhibition affect the cell cycle, and why is this significant in cancer therapy?

CDK8 inhibition can disrupt the cell cycle, slowing down or halting the uncontrolled cell division characteristic of cancer cells, making it a potential therapeutic strategy.

How does CDK8 influence the immune response in the tumor microenvironment?

CDK8 can modulate the expression of genes involved in immune response. Understanding its role in the tumor microenvironment may lead to novel immunotherapeutic strategies.

Are there ongoing clinical trials investigating the efficacy of CDK8 inhibitors in cancer patients?

Yes, several clinical trials are underway to assess the safety and effectiveness of CDK8 inhibitors as a targeted therapy for different types of cancer.